Reuters logo
BRIEF-FDA lifts hold on Seattle Genetics' phase 1 trials of vadastuximab talirine
March 6, 2017 / 12:02 PM / 9 months ago

BRIEF-FDA lifts hold on Seattle Genetics' phase 1 trials of vadastuximab talirine

March 6 (Reuters) - Seattle Genetics Inc

* FDA lifts clinical hold on seattle genetics’ phase 1 trials of vadastuximab talirine

* Seattle genetics inc - seattle genetics will resume two phase 1 trials of vadastuximab talirine

* Seattle genetics inc - will not resume phase 1/2 trial of vadastuximab talirine monotherapy in pre- and post-allogeneic transplant aml patients

* Seattle genetics inc - continuing to enroll our ongoing phase 3 randomized cascade trial in frontline older aml patients

* Seattle genetics inc - we are continuing to enroll our phase 1/2 trial in frontline high-risk myelodysplastic syndrome

* Seattle genetics-planned studies include phase 2 trial of vadastuximab talirine in combination with 7+3 chemotherapy in frontline younger aml patients

* Seattle genetics-additional risk mitigation measures will be implemented in all vadastuximab talirine studies

* Seattle genetics - will resume two phase 1 trials in aml and plan to initiate a randomized phase 2 trial during 2017 evaluating vadastuximab talirine Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below